A
MYLOID PLAQUES, COMposed predominantly of ␤-amyloid (A␤) peptides with COOH-termini ending in amino acid 40 (A␤ 40 ) and 42 (A␤ 42 ), accumulate progressively in the brains of patients with Alzheimer disease (AD). The exact cause of these lesions is not clear. Diffuse deposits of A␤ 42 are posited to be an initial form of A␤ plaques; in individuals with no AD dementia, they are rarely detected before age 50 years 1 and are considered indicative of "pathological aging" or preclinical AD. 2 In contrast, there have been consistent neuropathologic reports of diffuse cortical A␤ plaques in 30% to 38% of people with traumatic brain injury (TBI) regardless of their age. 3 Together with epidemiological studies, this neuropathologic evidence suggests that TBI is an environmental risk factor for the development of AD.
The molecular mechanism of A␤ plaque formation after TBI in humans is not known, but likely involves altered A␤ precursor protein (APP) production and/or metabolism, which occurs in animal TBI models. 4, 5 After TBI in humans, accumulation of APP fragments (including A␤) in damaged axons and plaques has been observed using immunohistochemical techniques. [6] [7] [8] Reduced levels of soluble A␤ have been detected in cerebrospinal fluid, 9 suggesting that reduced A␤ clearance may contribute to increased A␤ levels in brain tissue. To date, there have been no quantitative biochemical assessments of A␤ peptides and APP in human brain tissue after TBI. Given the potential synaptotoxic effects of soluble A␤ peptides and plaqueassociated fibrils in AD, [10] [11] [12] as well as beneficial effects of anti-A␤ interventions in animal models of AD, 13, 14 understanding postinjury changes in soluble A␤ could provide insight into the pathologic sequelae of TBI heretofore undetected in immunohistochemical studies. Accordingly, we examined changes in soluble A␤ peptides and APP levels relative to A␤ plaque deposition following severe TBI in humans.
METHODS
This study included 19 patients with TBI (Table) admitted to the University of Pittsburgh Medical Center for treatment of severe closed head injury (Glasgow Coma Scale score Ͻ9). Studies were approved by the institutional review board at the University of Pittsburgh; written informed consent was obtained from family members. The details of patient management were published previously. 8 All patients underwent decompressive craniectomy to relieve intractable cerebral swelling. Temporal cortex tissue removed for this purpose (that would normally be discarded) was used. One portion of each sample was fresh frozen and stored at −80°C for biochemistry; the adjacent tissue was fixed with 4% paraformaldehyde and processed for A␤ immunohistochemistry in our previous study, 8 which identified 2 groups of patients with TBI: those with diffuse A␤ plaques in the temporal cortex (plaque positive) and those lacking A␤ plaques (plaque negative) (Table) . Another set of frozen temporal cortex tissue samples was obtained through the University of Pittsburgh Alzheimer Disease Research Center Brain Bank post mortem from 18 clinically diagnosed and neuropathologically confirmed patients with AD (mean ± SD, age, 78.9 ± 8.7 years; postmortem interval, 7.3 ± 3.3 hours), and 5 neurologically healthy elderly individuals (mean ± SD, age, 74.8 ± 5.9 years; postmortem interval, 7.8 ± 3.7 hours). Because control surgical samples are not available from healthy young people, these older autopsy subjects were used to validate our biochemical measurements. Soluble A␤ peptides were assayed using fluorescent-based enzymelinked immunosorbent assay (Biosource, Camarillo, Calif ) with a capture antibody specific for the NH 2 -terminus of A␤ (amino acids 1-16) and detection antibodies specific for A␤ peptides A␤ or A␤ . ␤-Amyloid enzyme-linked immunosorbent assay levels were expressed as picomoles of A␤ and A␤ per gram of the wet weight of tissue. The APP was assayed by Western blot using an NH 2 -terminus-specific monoclonal APP antibody with a 1:1000 dilution (22C11; Roche, Basel, Switzerland), as described previously. 4 Statistical analyses were performed using the Mann-Whitney test and Spearman rank correlation test. Two-tailed P values less than .05 were considered statistically significant.
RESULTS
Demographic data were similar between the 2 TBI groups (Table) , with the exception of having fewer women than men and a lower frequency of the apolipoprotein E (APOE) ε4 allele in the A␤ plaque-negative group. Fifty percent of the patients with severe TBI and cortical plaques carried the APOE ε4 allele, a rate that was higher than expected, because approximately 20% to 25% of the white population is APOE ε4 positive. In the plaque-negative group, APOE ε4 allele frequency was lower (11%). Soluble A␤ and A␤ were detected in the temporal cortex of all patients with TBI, and there was a significant direct correlation between levels of these 2 A␤ species (Spearman rank correlation r =0.68; P=.0005). Soluble A␤ 1-42 levels were significantly higher in the plaquepositive group compared with the plaque-negative group (P = .0098) ( Table) , while A␤ 1-40 levels were comparable, resulting in a greater A␤ 1-42 /A␤ 1-40 ratio in the plaquepositive group (P=.012). There was a trend toward a correlation of higher soluble A␤ levels with greater A␤ plaque load in plaque-positive cases (not shown). The lowest levels of soluble A␤ 1-42 and A␤ 1-40 (10-fold and 5-fold lower, respectively, than the means of the population) were in the only APOE ε2 patient (APOE 2/3, plaque negative). As validation of the A␤ enzyme-linked immunosorbent assay procedure, A␤ 1-42 and A␤ 1-40 levels in the temporal cortex of patients with AD (mean±SD, A␤ 1-42 , 20.17±4.08 pmol/g of wet weight of tissue; A␤ 1-40 , 6.47±1.48 pmol/g of wet weight of tissue) and older control subjects (mean±SD, A␤ 1-42 ,0.86±0.13 pmol/g of wet weight of tissue; A␤ 1-40 , 0.33±0.05 pmol/g of wet weight of tissue) were similar to those reported previously. 15 To examine the effect of time on changes in soluble A␤ levels following TBI, we correlated A␤ levels with patients' time intervals between injury and surgical tissue extraction. Longer intervals between injury and extraction were directly correlated with higher A␤ 1-42 (r=0.50; P=.029) but not A␤ 1-40 levels.
Western blot analysis of APP revealed 2 major bands, at 115 and 105 kd, corresponding to expected molecular weights of major full-length APP isoforms (not shown). Both bands were prominent in all patients with TBI and did not differ significantly between plaque-positive (mean±SD, 5410±3653 optical density units) and plaquenegative TBI groups (mean±SD, 4351±1009 optical density units).
COMMENT
The selective increase in A␤ 1-42 levels in patients with severe TBI and cortical plaques could explain the predominance of A␤ 42 over A␤ 40 plaques reported in human TBI autopsy series 16, 17 and in our biopsy immunohistochemical study 8 ; A␤ 1-42 is more prone to aggregation and may initiate plaque formation, as observed in Down syndrome and early AD. 18 Increased A␤ 1-42 levels and A␤ plaque deposition were not associated with selectively higher APP production; because of considerable intersubject variability, full-length APP isoforms detected on our Western blots were comparable between plaque-positive and plaque-negative TBI groups. Altered APP metabolic processing, not the focus of the present study, may contribute to greater A␤ 1-42 production in patients with cortical plaques. Accumulation of COOH-terminus APP fragments inside neuronal cell bodies and axons, demonstrated previously in this and other populations, [6] [7] [8] 19 is in accord with this idea. In addition, postinjury changes in A␤ aggregation dynamics or clearance mechanisms may increase A␤ accumulation in brain tissue. For example, cerebrospinal fluid A␤ levels are decreased in patients with TBI, 9 suggesting impaired clearance and increased retention of A␤ in brain tissue after injury. In accordance with this idea, a recent in vivo positron emission tomography imaging study using Pittsburgh compound B (an amyloid-binding compound), demonstrated that a decreased cerebrospinal fluid A␤ 1-42 level (and not A␤ ) correlated with a greater Pittsburgh compound B retention (and therefore higher A␤ plaque load) during AD progression. 20 Cerebrospinal fluid A␤ levels in patients with severe TBI and cortical plaques compared with patients with severe TBI without cortical plaques remain to be determined.
Levels of A␤ after injury could also be influenced by patients' demographic factors. In the current study, both female patients and APOE ε4 carriers were more prevalent in the plaque-positive group. The effect of sex on A␤ levels and deposition after TBI is not known. As confirmed in the present study, the frequency of APOE ε4 is high in patients with TBI with A␤ plaques 21 ; the presence of this allele is also associated with a 10-fold increased risk for developing AD after TBI. 22 Although the APOE ε4 allele and female sex were associated with higher soluble A␤ levels overall, this difference was not statistically significant in the present study.
While our data demonstrate that plaque formation after TBI is associated with greater soluble A␤ 1-42 levels, we cannot determine the magnitude of these changes relative to uninjured age-matched controls, because fresh biopsy tissue from such subjects is not available. However, parallel assessment of A␤ levels in 2 positive control groups (postmortem tissue obtained from patients with AD and older controls) allows for translation of the levels detected in TBI samples (previously unknown) to the range of reported human brain A␤ levels, and provides a standard for future TBI studies in humans.
In addition to known mechanisms involving diffuse axonal injury and direct trauma in TBI, 23 elevation of soluble A␤ 1-42 levels may have additional injurious effects, such as lowering neuronal resistance to injury or death. 24 We saw no correlation of acute changes in soluble A␤ levels with outcome on the Glasgow Outcome Scale at 3 and 6 months. This could be because of modest sample size or lack of more sophisticated methods of outcome assessment. Alternatively, in long-term follow-up (years or decades), brain tissue accumulation of soluble A␤ monomers may lead to more progressive accrual of soluble A␤ oligomers, known to adversely affect cognitive function in mouse models, 25, 26 and insoluble A␤ fibrils. In this regard, chronic effects of postinjury increases in soluble A␤ 42 and A␤ plaque formation on functional outcome and increased incidence of AD later in life remain to be examined in long-term survivors of severe TBI.
CONCLUSIONS
Higher brain tissue levels of soluble A␤ 1-42 and the development of cortical A␤ plaques may predispose a subset of individuals with a brain injury to develop AD. Postinjury interventions that prevent or reduce such changes should be considered, especially in APOE ε4 carriers, as a therapeutic strategy to prevent progressive development of AD pathology and cognitive decline later in life.
